A CoronaVac, vaccine against Covid-19 from the chinese Sinovac Biotech packed not Brazil hair Butantan Institute, is safe and induces an immune response in adolescents and children aged 3 to 17 years, showed a study published on Monday.
According to Butantan, the results of the study published by Lancet were obtained through phase 1 and 2 clinical trials with 552 participants between October and December 2020 carried out in the Chinese province of Hebei. The study was carried out by Sinovac in partnership with Chinese institutions.
The rate of seroconversion of neutralizing antibodies, which indicates the production of antibodies against the coronavirus, was greater than 96% after 28 days of vaccination with two doses of the immunizing agent, according to the institute, which added that the observed adverse reactions were mild or moderate.
“The data, therefore, indicate an excellent safety profile and good neutralizing antibody titers induced by the immunizer, which supports a two-dose vaccine schedule for further studies in the group of children and adolescents,” said Butantan in a note.
According to Butantan, data relating to the study of CoronaVac in children and adolescents have already been sent to the National Health Surveillance Agency (Anvisa).
“The results indicate that the vaccine is also safe for children and young people. With the advancement of research, it will very soon be possible to attest to the effectiveness of Coronavac in this specific population”, said the president of Butantan, Dimas Covas, in the statement.
So far, only Pfizer’s vaccine has been approved for use in people under 18 in Brazil, being authorized for adolescents from 12 years of age.